WO2000044419A1 - Method and apparatus for percutaneously accessing a pressure activated implanted port - Google Patents
Method and apparatus for percutaneously accessing a pressure activated implanted port Download PDFInfo
- Publication number
- WO2000044419A1 WO2000044419A1 PCT/US2000/002268 US0002268W WO0044419A1 WO 2000044419 A1 WO2000044419 A1 WO 2000044419A1 US 0002268 W US0002268 W US 0002268W WO 0044419 A1 WO0044419 A1 WO 0044419A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- port
- access
- passage
- access tube
- implantable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0208—Subcutaneous access sites for injecting or removing fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/04—Tools for specific apparatus
Definitions
- the present invention relates generally to the design and use of medical devices, and more particularly to the design and use of an implantable port having a simplified design that establishes temporary access to a body lumen in the patient.
- Access to a patient's vascular system can be established by a variety of temporary and permanently implanted devices. Most simply, temporary access can be provided by the direct percutaneous introduction of a needle through the patient's skin and into a blood vessel. While such a direct approach is relatively simple and suitable for some applications, they are not suitable for hemodialysis, peritoneal dialysis, and hemofiltration. Such a direct approach is also inconvenient for other procedures, such as insulin or drug delivery procedures, which are repeated frequently over the lifetime of the patient.
- the port includes a chamber having an access region, such as a septum, where the chamber is attached to an implanted cannula which in turn is secured to a blood vessel.
- a septum In the case of veins, the cannula is typically indwelling, and in the case of arteries, the cannula may be attached by conventional surgical technique.
- Percutaneous access to a port through a septum is generally limited to small diameter, non-coring needles. Large diameter needles will core the septum, i.e. form permanent channels therethrough, which will destroy the septum after repeated uses.
- Implantable ports having an access aperture and internal valve mechanism for isolating the implanted cannula have also been proposed.
- One type of implantable valved port is described in a series of issued of U.S. patents which name William Ensminger as inventor.
- the Ensminger access ports have internal lumens for receiving a percutaneously introduced needle and an internal valve structure for isolating the port from an associated implanted cannula.
- the Ensminger ports have a needle- receiving aperture which is oriented at an inclined angle relative to the patient's skin.
- the Ensminger ports employ relatively entry ports having large funnel-like tapers and troughs so that needles can be introduced through many different sites in accordance with conventional procedures.
- the Ensminger patents do not describe port access using large diameter, coring needles, such as fistula needles.
- coring needles such as fistula needles.
- Representative Ensminger patents are listed in the Description of the Background Art below.
- the improved methods and apparatus should reduce patient trauma, reduce cost, simplify apparatus design, provide for reliable access to the vasculature, minimize the risk of infection to the patient, and preferably require only minor modifications to present procedures. At least some of these objectives will be met by the invention described hereinafter.
- Patents which name William Ensminger as an inventor include U.S. Patent Nos. 5,741,228; 5,702,363; 4,569,675; 4,534,759; 4,181,132; WO 97/47338; and WO 96/31246.
- Devices for hemodialysis or devices having one piece valves are described in U.S.
- Patent Nos. 4,892,518; 5,098,405; and 5,125,897 Implantable ports and subcutaneous catheters for connecting the ports for hemodialysis, peritoneal dialysis, and other procedures which may be useful in the present invention are described in co-pending application nos. 08/539,105; 08/724,948; 09/009,758;
- the present invention provides improved methods, apparatus, and kits for creating and establishing access to subcutaneously implanted ports for a variety of medical purposes such as drug delivery and the like.
- the present invention advantageously provides implantable ports of a simplified design and construction which open and close based on various levels of pressure differentials.
- the present invention preferably provides methods and apparatus which combine the advantages of a "buttonhole" access technique, such as low pain needle insertion and formation of a denervated tissue tract, with the advantages of subcutaneous port access, e.g. reliable performance and low failure rates, high blood and fluid flows through the port with minimum degradation of the blood or other fluid, and the ability to utilize an internal valve to provide improved isolation of the blood vessel or other accessed body lumen.
- a buttonhole access technique is described in commonly assigned, co-pending U.S. Patent Application No. 09/161,068 (Attorney Docket No. 17742-001420, filed on September 25, 1998), the full disclosure of which is incorporated herein by reference for all purposes.
- the flow passage has an upstream end and a downstream end, where at least one portion of the upstream end is adapted to sealingly engage an access tube that is inserted into said upstream end.
- This passage is optionally tapered so as to facilitate the sealing engagement with the access tube.
- the taper in the passage can also advantageously accommodate needles of slightly varying diameters.
- a pressure-responsive valve element is positioned in the flow passage downstream from the upstream portion so that the access tube can be fully inserted into said upstream portion without engaging the valve element.
- the pressure-responsive valve element is preferably closed in the absence of a differential pressure above a threshold level.
- the port according to the present invention has a body comprising a housing and a housing insert.
- the housing may be made of a noncorrosive material such as stainless steel or titanium while the insert is typically made of a compliant material such as silicone.
- the housing and housing insert may made from the same homogenous material.
- the implantable port design is preferably simplified by having the pressure-responsive valve element integrally formed with the insert. In this manner, the interior structure of the port may be simplified for cost-effective manufacturing. Use of such an integrated pressure valve element is possible in the port since not all medical applications may require the bidirectional flow capability used for such extracorporal procedures as hemodialysis and the like. Although such bidirectional flow may still be possible if sufficient suction or differential pressure is present, the pressure-responsive valve of the present embodiment is particularly suited for fluid infusion such as for drug delivery.
- the threshold level of pressure required to activate the valve is preferably about 2 psi.
- the port according to the present invention generally has an opening on the upstream end of the passageway with dimensions which correspond to those of the access tube, e.g. they will have similar diameters, or with an opening comprising a funnel having dimensions substantially larger than the access tube diameter.
- a funnel at the opening for directing the access tube into the opening is undesirable since it allows the user to penetrate the access tube through different access tracts.
- the downstream end of the passageway in the port body is preferably disposed at a 90° angle relative to the upstream end which receives the access tube.
- the passageway may be disposed at other angles in the passageway. The bend in the passageway prevents the access tube from contacting and damage the pressure-responsive valve element.
- a method for delivering a substance to a subcutaneous target site comprises percutaneously introducing an access tube to an implanted port having a flow passageway with an upstream end, a downstream end, and a valve element therein.
- the access tube is introduced to seat in the passage but the tube does not engage the valve element.
- the access tube and a seat interface in the passages form a seal. This minimizes needle damage to a fluid path sealing element of the port, something that plagues the performance of conventional ports.
- the substance is introduced into the flow passage through the access tube at a pressure sufficient to open the valve element to permit flow through the flow passageway to the target site.
- repeated percutaneous introductions of the access tube into the patient will create a unique tissue tract which becomes lined with scar tissue and has lessened nerve sensitivity, reducing patient trauma as the same tissue tract continues to be used for access.
- a sharpened element in order to assist in percutaneous introduction. That is, a blunt cannula may be able to pass inwardly through the established tissue tract.
- the access tube will have a diameter which is larger than that of the tissue tract which will have collapsed after the cannula was removed in the previous treatment protocol.
- the tissue tract will be dilated.
- the access intervals and time periods will depend at least in part on the procedures to be performed on the patient.
- patients undergoing insulin treatments will typically have the needle or cannula introducing step repeated at intervals of up to four times a day, usually for indefinite periods.
- the needle or cannula will be introduced in a consistent direction, e.g. generally normal or perpendicular to the skin surface through which it is being introduced, with the repeated access steps eventually creating the nerve depleted tissue tract described above.
- Kits according the present invention may comprise an implantable port together with instructions for use setting forth any of the methods described for implanting the port and creating a cannula access tract to the port.
- the port and the instructions for use will typically be packaged together, using any of the packages described hereinafter, and other kit components, such as a penetrating element, access tube, or the like, may also be provided.
- FIG. 1 is a cross-sectional view of a first embodiment of an implantable port according to the present invention
- Figs. 2-3 are cross-sectional views of another embodiment of an implantable port according to the present invention being accessed by an access tube
- Fig. 4A-4B show cross-sectional views of further embodiments of an implantable port according to the present invention
- Figs. 5-6 illustrate one technique for creating and accessing a subcutaneously implanted port according to the methods of the present invention
- Figs. 7-8 illustrate use of an access tube for creating and accessing a subcutaneously implanted port according to the methods of the present invention
- Fig. 9 illustrates a kit according to the present invention comprising a subcutaneously implantable port, a package, and instructions for use describing how to create an access tract according to the present invention.
- the methods and apparatus of the present invention for percutaneously accessing an implantable port is useful in a variety of long-term medical procedures such as insulin drug delivery and the like.
- the methods of the present invention may be performed with implantable ports having one, two, three, or more, discrete access ports which may be vertically or otherwise repeatedly aligned with the access tract to be percutaneously formed through overlying tissue.
- Such access tracts will be useful for repeated access to the aperture, where the aperture defines a specific target site through the overlying tissue.
- the use of valved ports provide for positive shutoff and isolation of the attached body lumen, and in particular provide for complete cessation of back bleeding when an access tube is removed from ports attached to blood vessels.
- a pressure-responsive valve element 40 is positioned in the flow passage 20 downstream from the upstream end or portion 22 of the passage.
- the pressure-responsive valve element 40 is a pressure-actuated slit valve that is optionally integrally formed in the housing insert 14 to define an integrally formed component.
- the pressure-responsive valve element 40 may be a separate element such as an articulating leaflet valve, preferably allowing flow in only one direction. Sufficient pressure differential, however, may still allow bidirectional flow if slit valves are used.
- the opening 50 may be positioned in a variety of orientations, such as on the side wall of upstream portion 22, depending on the configuration of the passage 20.
- the port 48 and other port embodiments may have the catheter 30 coupled to the port through a cannula 52 with a nipple 54, instead of integrated with the port as shown in Fig. 1.
- Fig. 4B shows a further embodiment of the port of the present invention where the pressure-activated valve 60 is located at a distal tip of the catheter 62.
- the fluid flows in a passage that extends from the port through the catheter.
- the port 64 used in this embodiment typically does not have a valve located within the port.
- the valve may be located at the distal tip of the catheter or anywhere along the catheter 62.
- a valve 66 shown in phantom
- a method for implanting the port 10 within the body of the patient will now be described.
- tissue tract of the present invention may be established at any time after a port has been subcutaneously implanted. In many instances, it will be desirable to begin creating the tissue tract at the time the port is initially implanted.
- a syringe S having a syringe needle N is used as the penetrating element, but it will be appreciated that this is not necessary for initial tissue tract formation.
- Other access tubes may be used during the initial periods.
- the penetrating element may be left in place transcutaneously through the skin for a time sufficient to at least begin forming the tissue tract, usually for at least one week, preferably for at least two weeks. After that initial time, the tissue penetrating element may be removed and the resulting tissue tract accessed using access tubes according to the method of the present invention described below.
- a particular advantage of this method for creating the access tract is that the tract will be formed simultaneously with healing of the surgical introduction of the port and associated subcutaneous cannula.
- a further advantage, when an access tube is used as the penetrating element, is that fluids may be introduced and removed from the port during the healing period.
- the port 10 will have an aperture or opening 25 which is preferably oriented to receive a vertically aligned needle. That is, the access needle N will preferably be percutaneously introduced through the skin surface in a direction which is normal to or perpendicular to the plane of the skin at the point where the needle is being introduced. While vertical access is preferred and may be accomplished using the exemplary ports of the present invention, percutaneous access according to the present invention may also be achieved used non-vertical access direction, i.e. where access is accomplished by penetrating a needle or other device at a relatively low angle relative to the skin, often between 15° and 45° relative to the skin surface.
- the port 10 of the present invention does not have a needle guide channel, trough, or extended funnel at the opening of passage 20 since such a funnel or trough may allow the user to penetrate the access tube through different access tracts.
- the access needle N After entering the port 10, the access needle N will preferably engage with a tapered portion of the upstream end 22 of passage 20 to form a seal.
- the needle N does not engage the valve element 40, which in the preferred embodiment, is located in a portion of the passage 20 oriented at a 90° to the upstream end 22.
- the access tube may inserted using a method as further described in commonly assigned, copending
- the access tube or needle N is inserted to establish a flow path with a lumen in cannula 30, where the cannula may be connected to a blood vessel or other body lumen or cavity, as described in detail in co-pending Application No. 08/856,641, filed on May 15, 1997.
- the access needle N may be aligned over the aperture 25 by manually feeling the top of the port 10.
- the port 10 is generally symmetric with the aperture 25 positioned in the center of the port. The user can feel the periphery of the port P and visually determine its center.
- the access needle N is then vertically penetrated through the skin and into the aperture, as shown in Fig. 8.
- the thickness of tissue T overlying the aperture is generally from 3 mm to 15 mm, as described above. Withdrawal of the needle will leave a tissue tract TT through the tissue T overlying the port 10 (as shown in Fig. 7). Because the internal valve element 40 of port 10 will have closed, fluid from the body lumen such as the peritoneum, a blood vessel, tissue catheter, or other cavities will be inhibited.
- Both the vertical orientation of needle entry and the valve which inhibits back bleeding or fluid backflow into the tissue tract after withdrawal of the needle, contribute to the lessening or elimination of scab formation and reduction in patient trauma and rapid healing in a non-fibrous manner.
- ports may be irrigated with anti-microbial cleaning fluids when a needle smaller than the needle seal diameter is used.
- a port 10 may be packaged together with instructions for use (LFU) in a kit.
- a conventional package 100 which may be in the form of a pouch, tray, box, tube, or the like, may be used to contain both the port and the instructions for use.
- Additional kit components such as a penetrating element, access tube, a catheter, or the like, may also be included in the kit.
- all kits components may be sterilized within the package, and the instructions for use may be set forth on a separate sheet of paper and/or on the packaging itself.
- the instructions may set forth any of the aspects of the method of the present invention for implanting the port or subsequently accessing the port using an access tube as described above.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- External Artificial Organs (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU34754/00A AU3475400A (en) | 1999-01-28 | 2000-01-28 | Method and apparatus for percutaneously accessing a pressure activated implantedport |
JP2000595721A JP2002535093A (en) | 1999-01-28 | 2000-01-28 | Method and apparatus for percutaneous access to a pressure-operated implantation port |
CA002361017A CA2361017A1 (en) | 1999-01-28 | 2000-01-28 | Method and apparatus for percutaneously accessing a pressure activated implanted port |
EP00913283A EP1154810A4 (en) | 1999-01-28 | 2000-01-28 | Method and apparatus for percutaneously accessing a pressure activated implanted port |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23941199A | 1999-01-28 | 1999-01-28 | |
US09/239,411 | 1999-01-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000044419A1 true WO2000044419A1 (en) | 2000-08-03 |
WO2000044419A9 WO2000044419A9 (en) | 2002-05-02 |
Family
ID=22902020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/002268 WO2000044419A1 (en) | 1999-01-28 | 2000-01-28 | Method and apparatus for percutaneously accessing a pressure activated implanted port |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1154810A4 (en) |
JP (1) | JP2002535093A (en) |
AU (1) | AU3475400A (en) |
CA (1) | CA2361017A1 (en) |
WO (1) | WO2000044419A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005072811A1 (en) * | 2004-01-29 | 2005-08-11 | Boston Scientific Scimed, Inc. | Dual well port device |
US9447892B2 (en) | 2008-05-21 | 2016-09-20 | Angiodynamics, Inc. | Pressure activated valve for high flow rate and pressure venous access applications |
US9895524B2 (en) | 2012-07-13 | 2018-02-20 | Angiodynamics, Inc. | Fluid bypass device for valved catheters |
US9933079B2 (en) | 2004-01-29 | 2018-04-03 | Angiodynamics, Inc. | Stacked membrane for pressure actuated valve |
US10500329B2 (en) | 2003-06-27 | 2019-12-10 | Angiodynamics, Inc. | Pressure actuated valve with improved biasing member |
US10610678B2 (en) | 2016-08-11 | 2020-04-07 | Angiodynamics, Inc. | Bi-directional, pressure-actuated medical valve with improved fluid flow control and method of using such |
US11612734B2 (en) | 2009-07-13 | 2023-03-28 | Angiodynamics, Inc. | Method to secure an elastic component in a valve |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5972277B2 (en) * | 2010-11-29 | 2016-08-17 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Chemical infusion pump drug delivery system for delivering at least two drugs |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5713859A (en) * | 1994-01-18 | 1998-02-03 | Vasca, Inc. | Implantable vascular device |
US5989239A (en) * | 1997-01-21 | 1999-11-23 | Vasca, Inc. | Method and apparatus for percutaneously accessing an implanted port |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4464178A (en) * | 1981-11-25 | 1984-08-07 | Dalton Michael J | Method and apparatus for administration of fluids |
US5554117A (en) * | 1990-03-01 | 1996-09-10 | Michigan Transtech Corporation | Implantable access devices |
US5125897A (en) * | 1990-04-27 | 1992-06-30 | Corpak, Inc. | Gastrostomy device with one-way valve and cuff pin |
ES2135402T3 (en) * | 1990-12-21 | 1999-11-01 | Abbott Lab | A PHARMACEUTICAL INFUSION DISTRIBUTOR. |
WO1993000129A1 (en) * | 1991-06-20 | 1993-01-07 | Milosevic Zeljko | Implantable port |
DE4129782C1 (en) * | 1991-09-07 | 1992-10-08 | Hans Dipl.-Ing. Dr.Med. 3015 Wennigsen De Haindl | |
US6007516A (en) * | 1997-01-21 | 1999-12-28 | Vasca, Inc. | Valve port and method for vascular access |
-
2000
- 2000-01-28 AU AU34754/00A patent/AU3475400A/en not_active Abandoned
- 2000-01-28 JP JP2000595721A patent/JP2002535093A/en not_active Withdrawn
- 2000-01-28 EP EP00913283A patent/EP1154810A4/en not_active Ceased
- 2000-01-28 CA CA002361017A patent/CA2361017A1/en not_active Abandoned
- 2000-01-28 WO PCT/US2000/002268 patent/WO2000044419A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5713859A (en) * | 1994-01-18 | 1998-02-03 | Vasca, Inc. | Implantable vascular device |
US5989239A (en) * | 1997-01-21 | 1999-11-23 | Vasca, Inc. | Method and apparatus for percutaneously accessing an implanted port |
Non-Patent Citations (1)
Title |
---|
See also references of EP1154810A4 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10500329B2 (en) | 2003-06-27 | 2019-12-10 | Angiodynamics, Inc. | Pressure actuated valve with improved biasing member |
US11628243B2 (en) | 2003-06-27 | 2023-04-18 | Angiodynamics, Inc. | Pressure actuated valve with improved biasing member |
WO2005072811A1 (en) * | 2004-01-29 | 2005-08-11 | Boston Scientific Scimed, Inc. | Dual well port device |
EP2468352A1 (en) * | 2004-01-29 | 2012-06-27 | Navilyst Medical, Inc. | Dual reservoir implantable access port |
US8267915B2 (en) | 2004-01-29 | 2012-09-18 | Navilyst Medical, Inc. | Dual well port device |
US9933079B2 (en) | 2004-01-29 | 2018-04-03 | Angiodynamics, Inc. | Stacked membrane for pressure actuated valve |
US9447892B2 (en) | 2008-05-21 | 2016-09-20 | Angiodynamics, Inc. | Pressure activated valve for high flow rate and pressure venous access applications |
US11679248B2 (en) | 2008-05-21 | 2023-06-20 | Angiodynamics, Inc. | Pressure activated valve for high flow rate and pressure venous access applications |
US11612734B2 (en) | 2009-07-13 | 2023-03-28 | Angiodynamics, Inc. | Method to secure an elastic component in a valve |
US9895524B2 (en) | 2012-07-13 | 2018-02-20 | Angiodynamics, Inc. | Fluid bypass device for valved catheters |
US10610678B2 (en) | 2016-08-11 | 2020-04-07 | Angiodynamics, Inc. | Bi-directional, pressure-actuated medical valve with improved fluid flow control and method of using such |
Also Published As
Publication number | Publication date |
---|---|
EP1154810A1 (en) | 2001-11-21 |
JP2002535093A (en) | 2002-10-22 |
AU3475400A (en) | 2000-08-18 |
EP1154810A4 (en) | 2003-01-02 |
CA2361017A1 (en) | 2000-08-03 |
WO2000044419A9 (en) | 2002-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6929631B1 (en) | Method and apparatus for percutaneously accessing a pressure activated implanted port | |
US6007516A (en) | Valve port and method for vascular access | |
US5989239A (en) | Method and apparatus for percutaneously accessing an implanted port | |
US6120492A (en) | Method and apparatus for percutaneously accessing an implanted port | |
US11690991B2 (en) | Graft-port hemodialysis systems, devices, and methods | |
US7056316B1 (en) | Valve port and method for vascular access | |
EP1016431B1 (en) | Implantable access devices | |
US5997524A (en) | Catheter assembly for percutaneous access to subcutaneous port | |
US7927325B2 (en) | Implantable pump connector for catheter attachment | |
US4772270A (en) | Inseparable port/catheter tube assembly and methods | |
US4781695A (en) | Implantable fluid dispenser | |
US20010056266A1 (en) | Implantable hemodialysis access device | |
EP1017443A1 (en) | Valve port assembly with interlock | |
EP1154810A1 (en) | Method and apparatus for percutaneously accessing a pressure activated implanted port | |
JPH08107934A (en) | Cap for subcutaneous embedment type medicinal liquid injecting port sleeve | |
WO2001032141A1 (en) | Valve port and method for vascular access |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2361017 Country of ref document: CA Ref country code: CA Ref document number: 2361017 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 595721 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000913283 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000913283 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWR | Wipo information: refused in national office |
Ref document number: 2000913283 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000913283 Country of ref document: EP |